The British medicines and Health Products Administration approved the covid-2 vaccine manufactured by Modena company of the United States as an adult booster on the 15th, saying that the new Modena vaccine can target two covid-1 strains including Omicron strain. The British medicines and health products administration said in a statement on the same day that in each newly approved dose of Modena bivalent covid-19 vaccine, half of the dose (25 micrograms) was directed against the original covid-19 strain and the other half dose (25 micrograms) was directed against the mutated novel coronavirus Omicron strain. The statement said the decision to approve the vaccine was based on clinical trial data. The trial data showed that the Modena bivalent covid-19 vaccine used as a booster needle would trigger a strong immune response to the original covid-19 strain and the Omicron subtype ba.1 strain. Exploratory analysis also found that this bivalent vaccine was effective against Omicron subtype strains ba.4 and ba 5 can also produce a good immune response. "The emergence of bivalent (covid-19) vaccines is good news, but it remains to be seen how much it will change," said Beattie kampman, director of the vaccine center at the University of London School of hygiene and tropical medicine (news agency)